Get the Stockscreener App
9.50
1.06%
0.10
After Hours:
9.50
Avalo Therapeutics Inc stock is traded at $9.50, with a volume of 8,758.
It is up +1.06% in the last 24 hours and up +35.71% over the past month.
Avalo Therapeutics Inc is a clinical stage biotechnology company focused on the treatment of immune dysregulation. The company's lead asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
See More
Previous Close:
$9.40
Open:
$9.21
24h Volume:
8,758
Relative Volume:
0.54
Market Cap:
$91.18M
Revenue:
$1.93M
Net Income/Loss:
$-31.54M
P/E Ratio:
-4.4393
EPS:
-2.14
Net Cash Flow:
$-30.68M
1W Performance:
-1.76%
1M Performance:
+35.71%
6M Performance:
-56.32%
1Y Performance:
+7,771%
1-Day Range:
$9.01
$9.50
1-Week Range:
$8.4926
$9.80
52-Week Range:
$0.0333
$34.46
Avalo Therapeutics Inc Stock (AVTX) Company Profile
Name
Avalo Therapeutics Inc
Sector
Industry
Phone
410-522-8707
Address
540 GAITHER ROAD, ROCKVILLE
Avalo Therapeutics Inc Stock (AVTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-24-21 | Initiated | RBC Capital Mkts | Outperform |
Avalo Therapeutics Inc Stock (AVTX) Latest News
Short Interest in Avalo Therapeutics, Inc. (NASDAQ:AVTX) Expands By 38.1% - Defense World
Avalo Therapeutics: Pioneering Biotech Solutions for Immune Disorders - The China Perspective
Affinity Asset Advisors LLC Acquires 35,000 Shares of Avalo Therapeutics, Inc. (NASDAQ:AVTX) - Defense World
Where are the Opportunities in (AVTX) - Stock Traders Daily
Logos Global Management LP Purchases New Position in Avalo Therapeutics, Inc. (NASDAQ:AVTX) - Defense World
How To Trade (AVTX) - Stock Traders Daily
Avalo Therapeutics (NASDAQ:AVTX) Stock Price Up 7.8% - Defense World
Avalo Therapeutics regains Nasdaq compliance - Investing.com
Avalo Announces Participation in September Investor Conferences - GlobeNewswire
Avalo Announces Participation in September Investor Conferences - StockTitan
Financial Health Report: Avalo Therapeutics Inc (AVTX)’s Ratios Tell a Tale - The Dwinnex
Trading (AVTX) With Integrated Risk Controls - Stock Traders Daily
Avalo Therapeutics, Inc. (NASDAQ:AVTX) Short Interest Down 9.6% in July - Defense World
Avalo Therapeutics (FRA:C6K0) Cash From Discontinued Investing Activities : €0.00 Mil (TTM As of Jun. 2024) - GuruFocus.com
Oppenheimer sees upside in Avalo Therapeutics stock as phase 2 trial nears - Investing.com
Avalo Therapeutics (NASDAQ:AVTX) Releases Earnings Results - Defense World
Avalo Therapeutics sees cash runway into 2027 - TipRanks
AVTX Stock Earnings: Avalo Therapeutics Misses EPS for Q2 2024 - InvestorPlace
Avalo Reports Second Quarter 2024 Financial Results and Provides Business Updates - citybiz
Avalo Reports Second Quarter 2024 Financial Results and Provides Business Updates - GlobeNewswire
Avalo Reports Second Quarter 2024 Financial Results and Provides Business Updates - StockTitan
Avalo Reports Second Quarter 2024 Financial Results and Provides Business Updates - Yahoo Finance
Avalo Therapeutics Inc expected to post a loss of $6.70 a shareEarnings Preview - XM
Natixis Lowers Stake in Avalo Therapeutics, Inc. (NASDAQ:AVTX) - Defense World
(AVTX) Long Term Investment Analysis - Stock Traders Daily
The 3 Best Personalized Nutrition Stocks to Buy Now - InvestorPlace
Avalo Therapeutics (NASDAQ:AVTX) Shares Down 2.1% - Defense World
Avalo Therapeutics welcomes new Chief Medical Officer - Investing.com
Avalo Therapeutics welcomes new Chief Medical Officer - Investing.com India
Avalo Therapeutics Welcomes Chief Medical Officer - Contract Pharma
Avalo Therapeutics Announces Appointment of Dr. Mittie Doyle as Chief Medical Officer - GlobeNewswire Inc.
Avalo Therapeutics Announces Appointment of Dr. Mittie Doyle as Chief Medical Officer - Yahoo Finance
Avalo Therapeutics begins Phase 2 trial for HS treatment By Investing.com - Investing.com South Africa
Avalo Therapeutics begins Phase 2 trial for HS treatment - Investing.com
Avalo Therapeutics Announces Active IND for AVTX-009, an anti-IL-1β mAb, to Treat Hidradenitis Suppurativa - GlobeNewswire
Avalo Therapeutics Announces Active IND for AVTX-009, an anti-IL-1β mAb, to Treat Hidradenitis Suppurativa - StockTitan
(AVTX) Technical Data - Stock Traders Daily
Avalo Therapeutics Names Seasoned Pharma Atty As CLO - Law360
Avalo Therapeutics, Inc. (NASDAQ:AVTX) Sees Significant Decrease in Short Interest - Defense World
Form DEFA14A Avalo Therapeutics, Inc. - StreetInsider.com
Avalo Therapeutics appoints new Chief Legal Officer By Investing.com - Investing.com Australia
Avalo Therapeutics Appoints Paul Varki as Chief Legal Officer - citybiz
Avalo Therapeutics appoints new Chief Legal Officer - Investing.com India
Matson CEO Cox sells over $1m in company stock By Investing.com - Investing.com
Avalo Therapeutics appoints new Chief Legal Officer By Investing.com - Investing.com
Avalo Therapeutics Announces Appointment of Paul Varki as Chief Legal Officer - ForexTV.com
Avalo Therapeutics Welcomes New Chief Legal Officer Paul Varki - TipRanks
Ani Pharmaceuticals executive sells over $1.1 million in company stock By Investing.com - Investing.com UK
Avalo Therapeutics Announces Appointment of Paul Varki as Chief Legal Officer - GlobeNewswire
Avalo Therapeutics Announces Appointment of Paul Varki as Chief Legal Officer - StockTitan
Avalo Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits - Quantisnow
Avalo Therapeutics Inc Stock (AVTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):